Single-cell RNA sequencing (scRNA-seq) and its insights into cellular heterogeneity in atherosclerosis
Vascular Pharmacology · 2025-06 · 159 · 107499
DOI: 10.1016/j.vph.2025.107499 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2025-06. Verfasst von Baixue Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, 6229 HX Maastricht, the Netherlands. Ele…. Hauptthemen laut MEDLINE: Atherosclerosis, Single-Cell Analysis, RNA-Seq, Transcriptome. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organization for Applied Scientific Research, European Commission, China Scholarship Council.
Abstract (Originalsprache)
Single-cell RNA sequencing (scRNA-seq) has transformed our understanding of cellular diversity in human biology, providing novel insights into disease mechanisms. In cardiovascular disease (CVD), scRNA-seq enables precise mapping of complex cell populations, uncovering unique cell types and states that influence disease progression and suggest new therapeutic targets. In atherosclerosis (AS), scRNA-seq has redefined plaque pathology by identifying distinct cell types, including endothelial cells (ECs), smooth muscle cells (SMCs), fibroblasts, macrophages, T cells, and B cells, each with specific roles in plaque stability, inflammation, and disease progression. In our review, we summarized these major cellular populations and their cellular heterogeneity in non-diseased and atherosclerotic aorta, as identified by scRNA-seq in mice and human tissues. We discussed conserved and species-specific subpopulations, their defining markers, and their functional implications in plaque progression. In addition, we integrated findings from scRNA-seq with experimental studies to highlight key molecular targets with therapeutic potential. In the future, these insights offer a refined cellular and molecular framework of atherosclerosis and may help the development of targeted interventions to promote plaque stabilization and reduce cardiovascular risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, 6229 HX Maastricht, the Netherlands. Electronic address: b.yu@maastrichtuniverisity.nl.
- Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia. Elec…
- Department of Pathology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, 6229 HX Maastricht, the Netherlands; Aachen Maastricht Institute for CardioRenal research (AMICARE), 52074 Aac…
Förderung
- Netherlands Organization for Applied Scientific Research
- European Commission
- China Scholarship Council
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- European Cooperation in Science and Technology
- H2020 Marie Skłodowska-Curie Actions
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
Zitieren
APA
Yu, B., Sopic, M., & Sluimer, J. C. (2025). Single-cell RNA sequencing (scRNA-seq) and its insights into cellular heterogeneity in atherosclerosis. Vascular Pharmacology, 159, 107499. https://doi.org/10.1016/j.vph.2025.107499
Vancouver
Yu B, Sopic M, Sluimer JC. Single-cell RNA sequencing (scRNA-seq) and its insights into cellular heterogeneity in atherosclerosis. Vascular Pharmacology. 2025;159:107499. doi:10.1016/j.vph.2025.107499
BibTeX
@article{Yu2025,
author = {Yu, Baixue and Sopic, Miron and Sluimer, Judith C},
title = {Single-cell RNA sequencing (scRNA-seq) and its insights into cellular heterogeneity in atherosclerosis},
journal = {Vascular Pharmacology},
year = {2025},
volume = {159},
pages = {107499},
doi = {10.1016/j.vph.2025.107499}
}
EUVIMED